Acta Scientific Paediatrics (ISSN: 2581-883X)

Review Article Volume 3 Issue 7

Presentation, Management and Pathogenesis of the SARS-CoV-2 in Children

Sam Hassan*

Associate Professor of Pediatric Medicine, Department of Pediatrics, Mediclinic City Hospital, Dubai, United Arab Emirates

*Corresponding Author: Sam Hassan, Associate Professor of Pediatric Medicine, Department of Pediatrics, Mediclinic City Hospital, Dubai, United Arab Emirates.

Received: April 29, 2020; Published: June 15, 2020



Background: The current pandemic due to the novel coronavirus (SARS-Cov-2) (Figure 1) that caused COVID-19 infection is the most prevalent challenge for mankind since the World War II. This is a review article about up-to-date studies of this global significant pandemic.

Methods and Results: Review of current and related researches published online in English language about SARS-CoV-2 particularly in children. For the purpose of the journal citation the references reduced from 119 reviewed articles to 49 references, hence some of the references will be referred to within the text. Until now June 2020, the confirmed cases of infection globally exceeding 6.5 million cases with a mortality rate just above 6%. The confirmed reported cases are not representing the tangible scale of the pandemic due to insufficient testing programs, asymptomatic cases and false negatives following upper respiratory swabs only. The pandemic started with an epicenter in Wuhan city in China and moved like a tsunami to a second epicenter in Europe particularly Italy and Spain before it landed in the United States and the UK and lastly emerged in South America and Africa. Both adults and children are at risk of the disease however the course of the infection is milder in children. Spread of the infection may happen from any infected individual to others. Death were reported more in adults particularly the elderly and patients with preexisted comorbidities. This article is a review of the current studies focusing on the nature of the virus, immunopathology, clinical presentation in children and shading light on management and control.

Conclusion: Children are less likely to show sever SARS-CoV-2 infection with lower mortality rate than adults, most likely due to their immune system. Possible causes are the molecular receptors used by the virus for host cell entry, the crossed immunity against common corona viruses and other causes need more studies. Children show milder, different or asymptomatic course, hence the number may be under-estimated. The overall consequences of the COVID-19 on children is yet to be understood especially in relation to pregnancy, new-born babies, educations, welfare and future. The post COVID-19 complications such as, psychological and mental impacts, respiratory complications and post-viral sequela yet to be identified.

Keywords:COVID-19; SARS-Cov-2; Coronavirus; Children; Novel Coronavirus; 2019-nCoV; HCoV; SARS; MERS



  1. Middle East respiratory syndrome coronavirus (MERS-CoV), WHO MERS Global Summary and Assessment of Risk (2020).
  2. Susanna KP Lau., et al. “Molecular Epidemiology of Human Coronavirus OC43 Reveals Evolution of Different Genotypes over Time and Recent Emergence of a Novel Genotype due to Natural Recombination”. Journal of Virology 21 (2011): 11325-11337.
  3. New results from research into COVID-19 on mink farms; News item 19-05-2020; Government of Netherlands (2020).
  4. Jarvis C., et al. “Impact of physical distance measures on transmission in the UK”. Center for Mathematical Modeling of Infectious Diseases (2020).
  5. Thevarajan I., et al. “Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19”. Nature Medicine 26 (2020): 453-455.
  6. Russell B., et al. “Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence”. Ecancer Medical Science 14 (2020): 1022.
  7. Wang Y., et al. “Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications”. Nature Immunology 15 (2014): 1009-1016.
  8. De Wit J., et al. “Editorial: Role of HLA and KIR in Viral Infections”. Frontiers in Immunology 7 (2016): 286.
  9. Guan W-J., et al. “Clinical Characteristics of Coronavirus Disease 2019 in China”. The New England Journal of Medicine (2020).
  10. W Liu., et al. “Detection of Covid-19 in Children in Early January 2020 in Wuhan China”. New England Journal of Medicine (2020).
  11. Shi Y., et al. “COVID-19 infection: the perspectives on immune responses”. Cell Death and Differentiation (2020).
  12. Ruf B R and Knuf M. “The burden of seasonal and pandemic influenza in infants and children”. The European Journal of Pediatrics 137 (2014): 265-276.
  13. Van Elden LJ., et al. “Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction”. The Journal of Infectious Diseases 189 (2004): 652-657.
  14. Hon KL., et al. “Clinical presentations and outcome of severe acute respiratory syndrome in children”. Lancet 361 (2003): 1701-1703.
  15. Li AM., et al. “Radiological and pulmonary function outcomes of children with SARS”. Pediatric Pulmonology 38 (2004): 427-433.
  16. Wong SF., et al. “Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome”. American Journal of Obstetrics and Gynecology 191 (2004): 292-297.
  17. Fagbo SF., et al. “Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013”. Journal of Medical Virology 89 (2017): 195-201.
  18. Assiri A., et al. “Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia”. Clinical Infectious Diseases 63 (2016): 951-953.
  19. Dong Y., et al. “Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China”. Pediatrics (2020).
  20. Wei Xia MD., et al. “Clinical and CT features in pediatric patients with COVID‐19 infection: Different points from adults”. Pediatric Pulmonology (2020): 1-6.
  21. Jaillon S., et al. “Sexual dimorphism in innate immunity”. Clinical Reviews in Allergy and Immunology 56 (2019): 308-321.
  22. Fried JA., et al. “The Variety of Cardiovascular Presentations of COVID-19”. Originally (2020).
  23. Helms J., et al. “Neurological Features in Sever SARS-CoV-2 Infection”. The NEJM (2020).
  24. Mao L., et al. “Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China”. The Journal of the American Medical Association Neurology (2020).
  25. Munoz AC., et al. “Late-Onset Neonatal Sepsis in a Patient with Covid-19”. The New England Journal of Medicine (2020).
  26. Baker SC., et al. “Human coronavirus-NL63 infection is not associated with acute Kawasaki disease”. Advances in Experimental Medicine and Biology 581 (2006): 523‐526.
  27. Riphagen S., et al. “Hyperinflammatory shock in children during COVID-19 pandemic”. The Lancet (2020).
  28. Sam Hassan., et al. “Post-Streptococcal Syndrome in a 5-Years Old Boy with Sever Vitamin D Deficiency Only Responding to Monoclonal Antibody: First Case Report”. American Journal of Pediatrics2 (2018): 25-30.
  29. Recalcati S. “Cutaneous manifestations in COVID-19: a first perspective”. The Journal of the European Academy of Dermatology and Venereology (2020).
  30. DeBiasi RL., et al. “Sever COVID-19 in children and Young adults in the Washington, DC Metropolitan Region”. The Journal of Pediatrics (2020).
  31. Galea S., et al. “The Mental Health Consequences of COVID-19 and Physical Distancing: The Need for Prevention and Early Intervention”. The Journal of the American Medical Association Internal Medicine (2020).
  32. Van Doremalen., et al. “Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1”. The New England Journal of Medicine 16 (2020): 1564-1567.
  33. Casanova L., et al. “Virus transfer from personal protective equipment to healthcare employees' skin and clothing”. Emerging Infectious Diseases 8 (2008): 1291-1293.
  34. Rivett L., et al. “Screening of healthcare workers for SARS-CoV-S highlights the role of asymptomatic carriage in COVID-19 transmission”. ELife (2020).
  35. Lytle CD and Sagripanti JL. “Predicted inactivation of viruses of relevance to biodefense by solar radiation”. Journal of Virology 22 (2005): 14244-14252.
  36. Xu Y., et al. “Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding”. Nature Medicine 26 (2020): 502-505.
  37. Rockx B., et al. “Comparative Pathogenesis of COVID-19”. MERS And SARS In A Non-Human Primate Model (2020).
  38. Wax RS and Christian MD. “Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients”. Canadian Journal of Anesthesia/Journal Canadien D’anesthésie (2020).
  39. Shalhoub S., et al. “IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study”. Journal of Antimicrobial Chemotherapy 70 (2015): 2129-2132.
  40. Adedeji AO., et al. “Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses”. Antimicrob Agents Chemother 58 (2014): 4894-4898.
  41. Lundin A., et al. “Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus”. PLOS Pathogens 10 (2014): e1004166.
  42. Rider TH., et al. “Broad-spectrum antiviral therapeutics”. PLoS One 6 (2011): e22572.
  44. Wu C., et al. “Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China”. JAMA Internal Medicine (2020).
  45. Lane R. “Sarah Gilbert: carving a path towards a COVID-19 vaccine”. The Lancet 10232 (2020).
  46. Addo M. “Safety, tolerability and immunogenicity of vaccine candidate MVA-MERS-S (2018).
  47. Zhou Q., et al. “Nosocomial Infections Among Patients with COVID-19, SARS and MERS: A Rapid Review and Meta-Analysis”. Med Rxiv (2020).
  48. To KK., et al. “Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study”. The Lancet Infectious Diseases (2020).
  49. He X., et al. “Temporal dynamics in viral shedding and transmissibility of COVID-19”. Nature Medicine (2020).


Citation: Sam Hassan. “Presentation, Management and Pathogenesis of the SARS-CoV-2 in Children”. Acta Scientific Paediatrics 3.7 (2020): 13-31.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is March 30, 2023.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US